A retrospective analysis in patients with non-metastatic breast cancer (n=509) showed a positive association between higher RANKL serum levels (measured by enzyme linked immune sorbent assay [ELISA]) and presence of disseminated tumor cells in the bone marrow and also with the development of bone metastases (21). Here, TNFSF11 is linked to breast carcinoma.